AMPK-mediated prevention of vascular dysfunction with metformin: Experimental and population-based evidence.

Soroush Mohammadi Jouabadi, Annika A Jüttner, Annique Claringbould, Rene de Vries, Ingrid M Garrelds, Usha Musterd-Bhaggoe, Bruno H Stricker, Maryam Kavousi, A H Jan Danser, Fariba Ahmadizar, Anton J M Roks

Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. · pubmed

Paper

Abstract

Metformin is increasingly recognised for its vasculoprotective effects, primarily through activation of AMP-activated protein kinase (AMPK). We combined population-based genetic epidemiology, with an ex vivo vascular model, to investigate the beneficial vascular effects of AMPK activation by metformin.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that metformin activates AMPK to prevent vascular dysfunction. This research is relevant as it explores mechanisms that could contribute to longevity by addressing vascular health, which is a critical aspect of aging and age-related diseases.

Author of this paper? Send a correction.